Strides Pharma Science Ltd · NSE:STAR

Strides Pharma Science — Q1 FY2025 Earnings Presentation

23 slides from Strides Pharma Science's earnings presentation, Jul 29, 2024

  1. Slide 1: Exchange filing cover letter for press release

    July 29, 2024 BSE Limited The National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Bandra-Kurla Complex Dalal Street, Mumbai – 400 001 Bandra (E) Mumbai - 400 051 Scrip code: 532531 Scrip code: STAR Dear Madam/ Sir, Sub: Press Release Please find enclosed herewith Pres

  2. Slide 2: Strides Delivers a Strong Q1FY25 with Revenues at ₹10,875m

    Press Release July 29, 2024 Strides Delivers a Strong Q1FY25 with Revenues at ₹10,875m; Revenue Growth of 16.7% YoY with an EBITDA Margin of 20% US Revenues at Our Historic Quarter High of $70m Q1FY2025 Performance Highlights ▪ Revenues at ₹10,875m, Grew 16.7% YoY in line with FY25 Outlook ▪ Gross M

  3. Slide 3: About Strides

    About Strides Strides, a global pharmaceutical company headquartered in Bengaluru, India, is listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR). The Company mainly operates in the regulated markets and has an “in Africa for Africa” strategy and an institutional bu

  4. Slide 4: Delivering with Momentum - Q1FY25 Results

    Delivering with Momentum Q1FY25 Results | July 29, 2024 Strides Pharma Science Limited 1

  5. Slide 5: Safe Harbor

    Safe Harbor Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "p

  6. Slide 6: Strides Delivers a Strong Q1FY25 with Revenues at ₹10,875m

    Strides Delivers a Strong Q1FY25 with Revenues at ₹10,875m Revenue Growth of 16.7% YoY with an EBITDA Margin of 20% Growth recorded across all major markets Q1FY25 Q1FY24 YoY Our emphasis on profitability, efficiency and Revenues ₹10,875m ₹9,320m 16.7%  growth has led to a strong performance across

  7. Slide 7: Stable Revenue Growth with Improved Margins

    Stable Revenue Growth with Improved Margins Q1FY25 Adjusted PAT at ₹839m and Reported PAT at ₹683m xx Revenue in $M Total Revenue (₹/$M) Gross Margin EBITDA & EBITDA Margin Adj. PAT (₹M) Gross Margin (₹M) Gross Margin (%) EBITDA (₹M) EBITDA Margin (%) $113 $125 $126 $128 $130 7,000 62% 2,500 22% 61.

  8. Slide 8: Strides Reaffirms FY25 Outlook

    Strides Reaffirms FY25 Outlook PARAMETERS FY25 OUTLOOK COMMENTS Q1FY25 STATUS UPDATE CONTINUING BUSINESS Growth is targeted to come in Revenue grew by 16.7% YoY, ahead of FY25 REVENUE REVENUE TO GROW AT H2FY25 based on global product outlook 12-15% YoY launches Achieved EBITDA of ₹2,170m for the qua

  9. Slide 9: US Market

    US Market • US Revenues at a Historic High of $70m in Q1FY25, Grew 24.5% YoY • Reaffirming FY25 Revenue Outlook of $285m - $300m • The US Business Poised to Achieve the ~$400m Objective by FY27-28 6

  10. Slide 10: US Revenues at a Historic High of $70m in Q1FY25

    US Revenues at a Historic High of $70m in Q1FY25, grew 24.5%YoY Reaffirming outlook of $285m - $300m for FY25 Year-on-Year Comparison (₹/$M) Highlights ▸ Q1FY25 Revenues at ₹5,851m ($70m), grew 24.5% YoY xx Revenue in $M YoY 24.5%  ▸ First full quarter of gSuprep with ~30% market share $70 ▸ Receiv

  11. Slide 11: Other Regulated Markets

    Other Regulated Markets • Other Regulated Markets Revenues at $41m, Grew by 17.8% YoY • Portfolio Maximization and Increased Focus on B2B Partnerships will Continue to Drive Growth 8

  12. Slide 12: Other Regulated Markets Revenues at $41m, grew 17.8% YoY

    Other Regulated Markets Revenues at $41m, grew 17.8% YoY Year-on-Year Comparison (₹/$M) Highlights ▸ All regulated markets ex-US form part of the Other Regulated Markets xx Revenue in $M YoY 17.8%  ▸ Q1FY25 Revenues at ₹3,385m ($41m), grew 17.8% YoY $41 $35 ▸ Robust demand for key products coupled

  13. Slide 13: Growth and Access Markets

    Growth and Access Markets • Growth Markets Positioned for Strong Growth via Geographical Expansion & New Products 10

  14. Slide 14: Growth Markets Revenues at $13m; Access Markets at $7m

    Growth Markets Revenues at $13m, grew 41.2% YoY Access Markets Revenues remain lumpy at $7m Year-on-Year Comparison (₹/$M) Growth Markets xx Revenue in $M YoY -6.2%  ▸ Growth Markets includes Africa operations and new geographies of LATAM, MENA, $21 $20 CIS, APAC ₹ 1,747 ₹ 1,639 ▸ Q1FY25 Revenues a

  15. Slide 15: Financial Performance

    Financial Performance • Strong Financial Discipline Enabled Profitability and Cashflow Generation 12

  16. Slide 16: Income Statement – Q1FY25

    Income Statement – Q1FY25 Income statement (₹m) Particulars Q1 FY25 Q1 FY24 YoY Q4 FY24 QoQ I. Revenue 10,875 9,320 16.7% 10,583 2.8% II. Material Costs 4,204 3,850 4,162 III. Gross Margin (I- II) 6,671 5,470 21.9% 6,421 3.9% Gross Margin % 61.3% 58.7% 264bps 60.7% 67bps a. Personnel Cost 2,122 1,67

  17. Slide 17: Net Debt reduced by ₹367m in Q1FY25

    Net Debt reduced by ₹367m in Q1FY25, Net Debt at ₹19,983m Current Net Debt to EBITDA stands at 2.3x – Tracking ahead of the outlook of <2x Particulars (In ₹m) Mar’24 Jun’24 • Credit Rating Upgrade to “CARE A, Stable ” in Q1FY25 • Significant investments in Q1FY25 on working capital and capex for fut

  18. Slide 18: Key Balance Sheet Ratios

    Key Balance Sheet Ratios Net Debt to Equity (x) Net Debt to EBITDA (x) Cash to Cash Cycle (Days) 5.27 140 1.08 129 129 0.98 0.94 2.72 2.30 FY23 FY24 Q1FY25 FY23 FY24 Q1FY25 FY23 FY24 Q1FY25 Current Ratio (x) RoCE (%) Fixed Asset Turnover Ratio (x) 16.31% 4.60 4.66 1.05 1.03 1.05 12.83% 3.09 4.48% FY

  19. Slide 19: OneSource Specialty Pharma Ltd

    OneSource Specialty Pharma Ltd (formerly known as Stelis BioPharma Ltd) 16

  20. Slide 20: OneSource – Q1FY25 Updates

    OneSource – Q1FY25 Updates OneSource (erstwhile Stelis) – Biologics and Steriscience – Complex and Specialty Soft Gelatin Capsules (Strides Business Drug-Device Combinations Business injectables (CMO+CDMO) Moving to OneSource) • Biologics division (Stelis) achieved revenue at • Complex and Specialty

  21. Slide 21: OneSource – Q1FY25 Key Business Updates

    OneSource – Q1FY25 Key Business Updates OneSource (erstwhile Stelis) - Biologics and Drug-Device Combinations Business Steriscience – Complex and Soft Gelatin Capsules Specialty injectables (Strides Business Moving Drug Device Combination (DDC) Drug Substance (CMO+CDMO) to OneSource) • Onboarded one

  22. Slide 22: Q1FY25 Earnings Call Details

    Q1FY25 Earnings Call Details invites you to interact with the senior management on Q1FY25 Performance Click here to pre-register and join without the operator July 29, 2024 3:30pm IST / 11:00am BST / 6:00am EDT / 6:00pm HKT Participants from the Management would be: Arun Kumar Badree Komandur Vikesh

  23. Slide 23: Thank You !

    Thank You ! Strides Pharma Science Limited CIN: L24230MH1990PLC057062 Corporate Office Strides House, Bannerghatta Road, Bengaluru - 560 076, India Tel.: +91 80 6784 0000/ 6784 0290 Email: Investor-Relations@strides.com Registered Office 201, Devavrata, Sector 17, Vashi, Navi Mumbai - 400 703, India

Strides Pharma Science — Q1 FY2025 Earnings Presentation on 6ix